By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Stem cell technology company Cellular Dynamics International and Madison, Wisconsin-based life sciences company Promega today announced plans to collaborate on validating predictive drug discovery toxicity tests that rely on CDI's induced pluripotent stem cells and cytotoxicity and cell viability assays from Promega.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The White House says ethical discussions about genome editing of the human germline are needed.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.